Myeloma clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 18 years and up
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).
San Francisco, California and other locations
Our lead scientists for Myeloma research studies include Alfred Chung, MD.